Table of Contents

Executive Summary

1 Industry Overview of Alzheimer's Disease Therapeutics and Diagnostics

• 1.1 Definition of Alzheimer's Disease Therapeutics and Diagnostics
• 1.2 Alzheimer's Disease Therapeutics and Diagnostics Segment by Type
  • 1.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 Biomarkers
  • 1.2.3 Cholinesterase inhibitors
  • 1.2.4 NMDA receptor antagonists
  • 1.2.5 Brain imaging
  • 1.2.6 Blood tests
• 1.3 Alzheimer's Disease Therapeutics and Diagnostics Segment by Applications
  • 1.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Drugs Market
  • 1.3.3 Diagnostics Market
• 1.4 Global Alzheimer's Disease Therapeutics and Diagnostics Overall Market
  • 1.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue (2014-2025)
  • 1.4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Production (2014-2025)
  • 1.4.3 North America Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)
  • 1.4.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)
  • 1.4.5 China Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)
  • 1.4.6 Japan Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)
  • 1.4.8 India Alzheimer's Disease Therapeutics and Diagnostics Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Alzheimer's Disease Therapeutics and Diagnostics
• 2.3 Manufacturing Process Analysis of Alzheimer's Disease Therapeutics and Diagnostics
• 2.4 Industry Chain Structure of Alzheimer's Disease Therapeutics and Diagnostics

3 Development and Manufacturing Plants Analysis of Alzheimer's Disease Therapeutics and Diagnostics

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Alzheimer's Disease Therapeutics and Diagnostics
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Alzheimer's Disease Therapeutics and Diagnostics Production and Capacity Analysis
• 4.2 Alzheimer's Disease Therapeutics and Diagnostics Revenue Analysis
• 4.3 Alzheimer's Disease Therapeutics and Diagnostics Price Analysis
• 4.4 Market Concentration Degree

5 Alzheimer's Disease Therapeutics and Diagnostics Regional Market Analysis

• 5.1 Alzheimer's Disease Therapeutics and Diagnostics Production by Regions
  • 5.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Production by Regions
  • 5.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Regions
• 5.2 Alzheimer's Disease Therapeutics and Diagnostics Consumption by Regions
• 5.3 North America Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.3.1 North America Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.3.2 North America Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Alzheimer's Disease Therapeutics and Diagnostics Import and Export
• 5.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.4.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.4.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Import and Export
• 5.5 China Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.5.1 China Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.5.2 China Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Alzheimer's Disease Therapeutics and Diagnostics Import and Export
• 5.6 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.6.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.6.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Alzheimer's Disease Therapeutics and Diagnostics Import and Export
• 5.7 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.7.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.7.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Import and Export
• 5.8 India Alzheimer's Disease Therapeutics and Diagnostics Market Analysis
  • 5.8.1 India Alzheimer's Disease Therapeutics and Diagnostics Production
  • 5.8.2 India Alzheimer's Disease Therapeutics and Diagnostics Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Alzheimer's Disease Therapeutics and Diagnostics Import and Export

6 Alzheimer's Disease Therapeutics and Diagnostics Segment Market Analysis (by Type)

• 6.1 Global Alzheimer's Disease Therapeutics and Diagnostics Production by Type
• 6.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Type
• 6.3 Alzheimer's Disease Therapeutics and Diagnostics Price by Type

7 Alzheimer's Disease Therapeutics and Diagnostics Segment Market Analysis (by Application)

• 7.1 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption by Application
• 7.2 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption Market Share by Application (2014-2019)

8 Alzheimer's Disease Therapeutics and Diagnostics Major Manufacturers Analysis

• 8.1 Namenda
  • 8.1.1 Namenda Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.1.2 Namenda Product Introduction, Application and Specification
  • 8.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Aricept
  • 8.2.1 Aricept Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.2.2 Aricept Product Introduction, Application and Specification
  • 8.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Exelon
  • 8.3.1 Exelon Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.3.2 Exelon Product Introduction, Application and Specification
  • 8.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Solanezumab
  • 8.4.1 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.4.2 Solanezumab Product Introduction, Application and Specification
  • 8.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Gantenerumab
  • 8.5.1 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.5.2 Gantenerumab Product Introduction, Application and Specification
  • 8.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Verubecestat
  • 8.6.1 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.6.2 Verubecestat Product Introduction, Application and Specification
  • 8.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Pfizer
  • 8.7.1 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.7.2 Pfizer Product Introduction, Application and Specification
  • 8.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Eisai
  • 8.8.1 Eisai Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.8.2 Eisai Product Introduction, Application and Specification
  • 8.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Actavis
  • 8.9.1 Actavis Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.9.2 Actavis Product Introduction, Application and Specification
  • 8.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Lundbeck
  • 8.10.1 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Production Sites and Area Served
  • 8.10.2 Lundbeck Product Introduction, Application and Specification
  • 8.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Daiichi Sankyo
• 8.12 Novartis
• 8.13 TauRx

9 Development Trend of Analysis of Alzheimer's Disease Therapeutics and Diagnostics Market

• 9.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Trend Analysis
  • 9.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Alzheimer's Disease Therapeutics and Diagnostics Regional Market Trend
  • 9.2.1 North America Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
  • 9.2.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
  • 9.2.3 China Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
  • 9.2.4 Japan Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
  • 9.2.5 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
  • 9.2.6 India Alzheimer's Disease Therapeutics and Diagnostics Forecast 2019-2025
• 9.3 Alzheimer's Disease Therapeutics and Diagnostics Market Trend (Product Type)
• 9.4 Alzheimer's Disease Therapeutics and Diagnostics Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Alzheimer's Disease Therapeutics and Diagnostics Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List

Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.

The global Alzheimer's Disease Therapeutics and Diagnostics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Alzheimer's Disease Therapeutics and Diagnostics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer's Disease Therapeutics and Diagnostics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Alzheimer's Disease Therapeutics and Diagnostics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Alzheimer's Disease Therapeutics and Diagnostics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests

Segment by Application
Drugs Market
Diagnostics Market